Drugs / ATB-1013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05573477 | Nov 2022 → Jan 2024 | essential hypertension, type 2 diabetes mellitus | Autotelicbio | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATB-1013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05573477 ↗ |
| Route | Oral | “Oral tablet” NCT05573477 ↗ |